Related Experiment Video
Updated: Dec 19, 2025
FISH for Pre-implantation Genetic Diagnosis
Published on: February 23, 2011
Outcomes of Preimplantation Genetic Testing for Single Gene Defects in a Privately Funded Period and Publicly Funded
Talya Shaulov1, Li Zhang1, Jin-Tae Chung1
1MUHC Reproductive Centre, Department of Obstetrics and Gynecology, Montreal, Quebec, Canada.
Insights
Public funding for preimplantation genetic testing for monogenic diseases (PGT-M) shows improved clinical pregnancy and live birth rates compared to private funding. These findings suggest funding models may influence outcomes and patient populations in assisted reproductive technologies.
Area of Science:
- Reproductive Medicine
- Genetics
- Public Health
Background:
- Preimplantation genetic testing for monogenic diseases (PGT-M) is crucial for couples at risk of inherited disorders.
- Assessing the impact of funding models on PGT-M outcomes is essential for healthcare policy.
Purpose of the Study:
- To compare the outcomes of PGT-M cycles between privately funded periods (PRP) and publicly funded periods (PUP).
- To evaluate the influence of funding structures on clinical and embryological success rates in IVF-PGT-M.
Main Methods:
- A retrospective cohort study analyzed data from a North American tertiary center.
- Compared 56 PGT-M cycles (PRP: March 1998-July 2010) with 59 PGT-M cycles (PUP: August 2010-May 2015).
- Defined a PGT-M cycle as one biopsy procedure from one or serial IVF cycles.
Main Results:
- Clinical pregnancy rates (CPR) per PGT-M cycle were significantly higher in the PUP (52.5%) versus PRP (30.4%) (p=0.021).
- Live birth rates (LBR) per PGT-M cycle were also significantly higher in the PUP (40.9%) versus PRP (21.5%) (p=0.037).
- Sub-analysis within PUP showed higher CPR and LBR for cycles with single embryo transfer.
Conclusions:
- Transition to public funding and single embryo transfer guidelines had minimal impact on embryological outcomes but improved clinical results.
- Public funding was associated with lower rates of multiple pregnancies.
- Different patient populations may utilize private versus public funding systems for PGT-M.
Background:
The purpose of this study was to assess whether the outcomes from IVF-preimplantation genetic testing (IVF-PGT) cycles for single gene defects (SGD) (PGT-M) differ between a privately funded period (PRP) and publicly funded period (PUP).
Methods:
A retrospective cohort study was conducted in a North-American single tertiary center. The PRP (March 1998 to July 2010) comprised 56 PGT-M cycles from 58 IVF cycles in 38 couples, and the PUP (August 2010 to May 2015) comprised 59 PGT-M cycles from 87 IVF cycles in 38 couples. One PGT-M cycle is defined as one biopsy procedure from one or serial IVF cycles. A p-value of 0.05 was considered statistically significant.
Results:
The clinical pregnancy rates (CPR) per PGT-M cycle were 30.4% and 52.5% in each period, respectively (p=0.021). The live birth rates (LBR) per PGT-M cycle were 21.5% versus 40.9% in each period, respectively (p=0.037). A sub-analysis within the PUP comparing 39 PGT-M cycles from 39 IVF cycles with 20 PGT-M cycles from 49 IVF cycles yielded CPRs per PGT-M cycle of 64.1% and 30.0% and LBRs per PGT-M cycle of 53.8% and 15.0%, in each group, respectively (p< 0.05 for both).
Conclusion:
The transition from private to public funding and a single embryo transfer (ET) guideline has little impact on embryological and clinical outcomes of PGT-M cycles, and results in lower rates of multiple pregnancies. However, these two systems may serve different populations.
